Not yet recruiting
Diagnosis of Women With ANOCA
NCT07802457· Source
Recruiting
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895· Phase 1/2· Source
Not yet recruiting
Exercise Therapy for Women With ANOCA
NCT07733986· Source
Not yet recruiting
Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
NCT07682129· Phase 2· Source
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995· Phase 3· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· Phase 2/3· Source
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Source
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771· Phase 2· Source
Recruiting
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
NCT07037862· Phase 1/2· Source
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· Phase 3· Source
Recruiting
Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients
NCT06861361· Source
Active, not recruiting
FARAPULSE Workflow Assessment Registry
NCT06656884· Source
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479· Phase 3· Source
Active, not recruiting
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
NCT06557798· Source
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357· Phase 1/2· Source
Recruiting
Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)
NCT06280781· Source
Recruiting
Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
NCT05655078· Source
Enrolling by invitation
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
NCT05932615· Source
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058· Phase 2· Source
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617· Phase 3· Source
Active, not recruiting
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
NCT05701358· Source
Recruiting
A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis
NCT06461208· Phase 3· Source
Active, not recruiting
FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
NCT05466799· Phase 2· Source
Recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904· Phase 3· Source
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562· Phase 3· Source
Recruiting
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
NCT05611801· Phase 3· Source
Recruiting
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
NCT04939935· Phase 3· Source
Active, not recruiting
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
NCT05614102· Phase 1· Source
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085· Phase 3· Source
Recruiting
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
NCT05613023· Phase 3· Source
Recruiting
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
NCT05185739· Phase 2· Source
Recruiting
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
NCT05102019· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136· Phase 2· Source
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716· Phase 1/2· Source
Active, not recruiting
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896· Phase 3· Source
Recruiting
Methods of T Cell Depletion Trial (MoTD)
NCT04888741· Phase 2· Source
Active, not recruiting
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421· Phase 3· Source
Active, not recruiting
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT04663347· Phase 1/2· Source
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750· Phase 1/2· Source
Active, not recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
NCT04246086· Phase 1/2· Source
Active, not recruiting
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945· Phase 3· Source
Active, not recruiting
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04181827· Phase 3· Source
Recruiting
The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study
NCT04204915· Source
Active, not recruiting
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
NCT04164901· Phase 3· Source
Recruiting
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
NCT04116502· Phase 3· Source
Active, not recruiting
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
NCT03614260· Source
Active, not recruiting
Global Fenestrated Anaconda Clinical STudy
NCT03180996· Source
Recruiting
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181· Phase 3· Source
Active, not recruiting
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
NCT04116047· Phase 3· Source
Active, not recruiting
Prostate Advances in Comparative Evidence
NCT01584258· Phase 3· Source